NCT06878976
Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder
Enrolling by Invitation
PHASE3Ages 18–56InterventionalTreatmentAxsome Therapeutics, Inc.
~300 participants
Updated 2025-11-25 on ClinicalTrials.gov
What's tested:Solriamfetol 75mg, 150 mg, or 300 mg
At a glance
Recruiting sites
0 of 31 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Long-term Safety
Measured over Up to 52 weeks.
Conditions
Where it's being run
31 sites across 15 statesFlorida7
California5
Texas4
Ohio3
New York2
Connecticut1
Georgia1
Kansas1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Completion of the treatment period in Study SOL-BED-301.
Able to comply with study procedures.
Exclusion
Significant change in vital signs, medical history or concomitant medications since enrolling in the SOL-BED-301 study which, in the opinion of the Investigator or the Medical Monitor, would render the subject unsuitable to receive solriamfetol or participate in the study.
What this trial measures
- Long-term SafetyUp to 52 weeks.
Incidence of treatment-emergent adverse events following dosing with solriamfetol